Trials Sponsors Conditions Drugs Pricing

Conditions

Neuromuscular Blockade

Keywords

Residual nerve blockadeNeuromuscular monitoringResidual curarizationNeuromuscular blocking agents

Outcome Measures

Primary Outcomes (2)

Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing Neuromuscular Blocking Agent (NMBA) (Yes/no)
in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours
Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing NMBA (Succinylcholine) (Yes/no)
in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours

Secondary Outcomes (6)

Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA
in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours
Number of Participants With and Without Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no)
in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours
Number of Participants With and Without Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no)
in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours
Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively
in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 180 minutes
Number of Participants With and Without Mild Oxygen Desaturation (<90%, But >80%) in Cases Receiving a Non-depolarizing NMBA

Study Arms (1)

Eligible patients

Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection. Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.

Drug: RocuroniumDrug: SuccinylcholineDrug: CisatracuriumDrug: MivacuriumDevice: Objective neuromuscular monitoring (acceleromyography)Drug: SugammadexDrug: Neostigmine

Interventions

RocuroniumDrug

Eligible patients

SuccinylcholineDrug

Eligible patients

Cisatracurium

Eligibility Criteria

Age15 Years+

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients who received general anaesthesia with neuromuscular blockade

You may qualify if:

Patients who received general anaesthesia with neuromuscular blockade in one of the 7 hospitals providing data for the study in the last 18 months up until the time of data collection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Jakob Louis Thomsen
Otherlead
Merck Sharp & Dohme LLC
Industrycollaborator

Study Sites (1)

Herlev Hospital

Herlev, Denmark

MeSH Terms

Interventions

RocuroniumSuccinylcholinecisatracuriumMivacuriumSugammadexNeostigmine

Intervention Hierarchy (Ancestors)

AndrostanolsAndrostanesSteroidsFused-Ring CompoundsPolycyclic CompoundsCholineTrimethyl Ammonium CompoundsQuaternary Ammonium CompoundsAmines

Results Point of Contact

Title: Dr. JLD Thomsen
Organization: Herlev Hospital, research unit, anesthesia

Study Officials

Jakob L Thomsen, MD
Sponsor principal investigator
PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee: No
Restrictive Agreement: No

Enrollment

30,430 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: OTHER
Time Perspective: CROSS SECTIONAL
Target Duration: 1 Day
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: MD

Study Record Dates

First Submitted

September 9, 2016

First Posted

September 26, 2016

Study Start

October 1, 2016

Actual (reported)

Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (6)

Study Arms (1)

Eligible patients

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Documents

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (6)

Study Arms (1)

Eligible patients

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Documents

Locations